6/27/2025

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg...

Source: Finnhub

6/26/2025

Source: SeekingAlpha

6/26/2025

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management highlighted the expanding contribution from its newer neurology and rare disease products, such as LEQEMBI, SKYCLARYS, and ZURZUVAE, which now comprise nearly half of product revenue. CEO Chris Viehbacher described this as evidence of a “new Biogen” emerging, with these products gaining commercial traction and benefiting from expanded approvals, particularly in Europe and Brazil.

Source: Yahoo

6/25/2025

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity and secured 4 nominations on the Pharma shortlist for its campaigns related to Friedreich’s ataxia. This marks a significant presence for Biogen, […]

Source: Yahoo

6/25/2025

The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong

Source: Yahoo

6/25/2025

CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e

Source: Yahoo

6/25/2025

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re

Source: Yahoo

6/24/2025

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

Source: Yahoo

6/23/2025

Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness. About 255 participants will be included in the randomized, double-blind […]

Source: Yahoo

6/22/2025

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here.

Source: SeekingAlpha

6/20/2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been […]

Source: Yahoo

6/19/2025

The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.

Source: Yahoo

6/18/2025

CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity

Source: Yahoo

6/18/2025

H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b

Source: Yahoo

6/18/2025

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWS

Source: Yahoo

6/18/2025

Biogen Inc. announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich...

Source: Finnhub

6/17/2025

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Source: Yahoo

6/17/2025

Biogen Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

6/17/2025

Cambridge, UK, 17 June 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Dr. Stefan Härtle as Chief Development Officer, effective immediately. Stefan brings almost 20 years of pharmaceutical research and development experience to Maxion, most recently serving as Head of Clinical Pharmacology at MorphoSys, which was acquired by Novartis

Source: Yahoo

6/16/2025

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Source: DowJones